Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1

Journal of Virology

Volumn 71, Issue 4, 1997, Pages 2799-2809

  Binley, James M ^a   Klasse, Per Johan ^b   Cao, Yunzhen ^a   Jones, Ian ^c   Markowitz, Martin ^a   Ho, David D ^a   Moore, John P ^a,d  

^a ROCKEFELLER UNIVERSITY   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NATURAL ENVIRONMENT RESEARCH COUNCIL   (United Kingdom)

^d AARON DIAMOND AIDS RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; IMMUNOGLOBULIN G; PROTEINASE INHIBITOR; RITONAVIR; VIRUS ENVELOPE PROTEIN;

ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE COMPLEX DEPOSITION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEROCONVERSION; T LYMPHOCYTE;

EID: 0030897105     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.71.4.2799-2809.1997     Document Type: Article

References (100)

1. Ahmed, R., and D. Gray. 1996. Immunological memory and protective immunity: understanding their relation. Science 272:54-59.
2. Albert, J., B. Abrahamsson, K. Nagy, E. Aurelius, H. Gaines, G. Nyström, and E. M. Fenyö. 1990. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4:107-112.
3. Allan, J. S., J. E. Coligan, F. Barin, J. Sodroski, C. A. Rosen, W. A. Haseltine, T.-H. Lee, and M. Essex. 1985. Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science 228:1091-1094.
4. Amadori, A., A. DeRossi, G. P. Faulkner-Valle, and L. Chieco-Bianchi. 1988. Spontaneous in vitro production of virus-specific antibody by lymphocytes from HIV-infected subjects. Clin. Immunol. Immunopathol. 46:342-351.
5. Amadori, A., R. Zamarchi, V. Ciminale, A. Del Mistro, S. Siervo, A. Alberti, M. Colombatti, and L. Chieco-Bianchi. 1989. HIV-1 specific B cell activation: a major constituent of spontaneous B cell activation during HIV-1 infection. J. Immunol. 143:2146-2152.
6. Andrieu, J. M., D. Eme, A. Venet, C. Audroin, J. M. Tourani, M. Stern, D. Israel-Biet, K. Beldjord, F. Driss, and P. Even. 1988. Serum HIV antigen and anti-p24 antibodies in 200 HIV seropositive patients: correlation with CD4 and CD8 lymphocyte subsets. Clin. Exp. Immunol. 73:1-5.
7. Arendrup, M., C. Neilson, J.-E. Hansen, C. Pederson, L. Matheison, and J. O. Neilson. 1992. Autologous HIV-1 neutralizing antibodies: emergence of neutralizing-resistant escape virus and subsequent development of escape virus neutralizing antibodies. J. Acquired Immune Defic. Syndr. 5:303-307.
8. Arendrup, M., A. Sönnerborg, B. Svennerholm, L. Åkerblom, C. Nielsen, H. Clausen, S. Olofsson, J. O. Nielsen, and J.-E. S. Hansen. 1993. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape. J. Gen. Virol. 74:855-863.
9. Bachmann, M. F., U. Hoffman Rohrer, T. M. Kundig, K. Burkri, H. Hengartner, and R. M. Zinkernagel. 1993. The influence of antigen organization on B cell responsiveness. Science 262:1448-1451.
10. Bachmann, M. F., T. M. Kündig, C. P. Kalberer, H. Hengartner, and R. M. Zinkernagel. 1994. How many specific B cells are needed to protect against a virus? J. Immunol. 152:4235-4241.
11. Barbas, C. F., III, T. A. Collet, W. Amberg, P. Roben, J. M. Binley, D. Hoekestra, D. Cababa, T. M. Jones, R. A. Williamson, G. R. Pilkington, N. L. Haigwood, E. Cabezas, A. C. Satterthwait, I. Sanz, and D. R. Burton. 1993. Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. J. Mol. Biol. 230:812-823.
12. Beckman, E. M., S. A. Porcelli, C. T. Morita, S. M. Behar, S. T. Furlong, and M. B. Brenner. 1994. Recognition of lipid antigen by CD-1-restricted alpha/beta (+) T cells. Nature 372:691-694.
13. Bélec, L., T. Dupré, T. Prazuck, C. Tévi-Bénissan, J.-M. Kanga, O. Pathey, X.-S. Lu, and J. Pillot. 1995. Cervicovaginal overproduction of specific IgG. Human immunodeficiency virus (HIV) contrasts with normal or impaired IsA local response in HIV infection. J. Infect. Dis. 172:691-697.
14. Bélec, L., A. J. Georges, M.-C. Hallouin, A. S. Mohamed, L. Morand-Joubert, and M.-C. Georges-Courbot. 1996. Human T-lymphotropic virus type 1 excretion and specific antibody response in paired saliva and cervicovaginal secretions. AIDS Res. Hum. Retroviruses 12:157-167.
15. Belshe, R. B., B. S. Graham, M. C. Keefer, G. J. Gorse, P. Wright, R. Dolin, T. Matthews, K. Weinhold, D. P. Bolognesi, R. Sposto, D. M. Stablein, T. Twaddell, P. W. Berman, T. Gregory, A. E. Izu, M. C. Walker, and P. Fast for the NIAID AIDS Vaccine Clinical Trials Network. 1994. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. J. Am. Med. Soc. 272:475-480.
16. Benner, R., A. van Oudenaren, M. Björklund, F. Ivars, and D. Hlomberg. 1982. "Background" immunoglobulin production: measurement, biological significance and regulation. Immunol. Today 3:243-245.
17. Brown, A. E., M. T. Vahey, S. Y. J. Zhou, R. C.-Y. Chung, N. M. Ruiz, D. Hofheinz, J. R. Lane, D. L. Mayers, and the RV43 Study Group. 1995. Quantitative relationship of circulating p24 antigen with human immunodeficiency virus (HIV) RNA and specific antibody in HIV-infected subjects receiving antiretroviral therapy. J. Infect. Dis. 172:1091-1095.
18. Cao, Y., G. M. Shaw, M. S. Saag, R. Kokka, J. Todd, M. Urdea, and D. D. Ho. 1995. Comparison of branched DNA (bDNA) amplification technique with end-point dilution culture, p24 antigen assay and polymerase chain reaction (PCR) in the quantitation of HIV-1 in plasma. AIDS Res. Hum. Retroviruses 11:353-361.
19. Cao, Y., L. Qin, L. Zhang, J. Safrit, and D. D. Ho. 1995. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N. Engl. J. Med. 332:201-208.
20. Castaño, A. R., S. Tangri, J. E. W. Miller, H. R. Holcombe, M. R. Jackson, W. D. Huse, M. Kronenberg, and P. A. Peterson. 1995. Peptide binding and presentation by mouse CD1. Science 269:223-226.
21. Cheingsong-Popov, R., C. Panagiotidi, S. Bowcock, A. Aronstam, J. Wadsworth, and J. Weber. 1991. Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection. Br. Med. J. 302:23-26.
22. Conley, A. J., J. A. Kessler II, L. J. Boots, P. M. McKenna, W. A. Schleif, E. A. Emini, G. E. Mark III, H. Katinger, E. K. Cobb, S. M. Lunceford, S. R. Rouse, and K. K. Murthy. 1996. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J. Virol. 70:6751-6758.
23. Connor, R. I., H. Mohri, Y. Cao, and D. D. Ho. 1993. Increased viral burden and cytopathicity correlate temporally with CD4+ lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J. Virol. 67:1772-1777.
24. Doms, R. W., R. A. Lamb, J. K. Rose, and A. Helenius. 1993. Folding and assembly of viral membrane proteins. Virology 193:545-562.
25. Embretson, J., M. Zupanici, J. L. Ribas, A. Burke, P. Racz, K. Tenner-Raez, and A. T. Haase. 1993. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 362:359-362.
26. Fauci, A. S. 1993. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 262:1011-1018.
27. Fenouillet, E., N. Blanes, A. Coutellier, and J. C. Gluckman. 1993. Monitoring of antibodies against human immunodeficiency virus type 1 p25 core protein as a prognostic marker. J. Infect. Dis. 166:611-616.
28. Fenouillet, E., N. Blanes, A. Coutellier, and J. C. Gluckman. 1993. Relationship between anti-p24 antibody levels and p24 antigenemia in HIV-infected patients. AIDS Res. Hum. Retroviruses 9:1251-1255.
29. Fenouillet, E., J. C. Gluckman, and I. M. Jones. 1994. Functions of HIV envelope glycans. Trends Biochem. Sci. 19:65-70.
30. Gallaher, W. R., J. M. Ball, R. F. Garry, A. M. Martin-Amedec, and R. C. Montelaro. 1995. A general model for the surface glycoproteins of HIV and other retroviruses. AIDS Res. Hum. Retroviruses 11:191-202.
31. Gauduin, M.-C., P. Maddon, D. Burton, and R. A. Koup. Personal communication.
32. Gelderblom, H. R. 1991. Assembly and morphology of HIV: potential effect of structure on viral function. AIDS 5:617-638.
33. Graham, B. S., and P. F. Wright. 1995. Candidate AIDS vaccines. N. Engl. J. Med. 333:1331-1339.
34. Gray, D. 1993. Immunological memory. Annu. Rev. Immunol. 11:49-77.
35. Groopman, J. E., P. M. Benz, R. Ferriani, K. Mayer, J. D. Allan, and L. A. Weymouth. 1987. Characterization of serum neutralization response to the human immunodeficiency virus (HIV). AIDS Res. Hum. Retroviruses 3:71-85.
36. Haase, A., K. Henry, M. Zupancic, G. Sedgewick, R. A. Faust, H. Melroe, W. Cavert, K. Gebhard, K. Staskus, Z.-Q. Zhang, P. J. Dailey, H. H. Balfour, Jr., A. Erice, and A. S. Perelson. 1996. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 274:985-989.
37. Hariharan, K., P. L. Nara, L. A. Shabazz, J. A. McCutchan, and C.-Y. Kang. 1994. Analysis of B cell repertoire specific to the neutralizing epitopes of glycoprotein 120 in HIV-infected individuals. AIDS Res. Hum. Retroviruses 10:1629-1637.
38. Harrer, T., E. Harrer, S. A. Kalams, T. Elbeik, S. I. Staprans, M. B. Feinberg, Y. Cao, D. D. Ho, T. Yilma, A. M. Caliendo, R. P. Johnson, S. P. Buchbinder, and B. D. Walker. 1996. Strong cytotoxic T cells and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res. Hum. Retroviruses 12:585-592.
39. Haynes, B. F., G. Pantaleo, and A. S. Fauci. 1996. Toward an understanding of the correlates of protective immunity to HIV infection. Science 271:324-328.
40. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
41. Hogervorst, E., S. Jurrians, F. de Wolf, A. van Wijk, A. Wiersma, M. Valk, M. Roos, B. van Gemen, R. Coutinho, F. Miedema, and J. Goudsmit. 1995. Predictors for non-and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. J. Infect. Dis. 171:811-821.
42. Inaba, K., R. M. Steinman, W. C. Van Voorhis, and S. Muramatsu. 1983. Dendritic cells are critical accessory cells for thymus-depcndent antibody responses in mouse and in man. Proc. Natl. Acad. Sci. USA 80:6041-6045.
43. Jiang, W., W. J. Swiggard, C. Heuffler, M. Peng, A. Mirza, R. M. Steinman, and M. C. Nussenzweig. 1995. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 375:151-155.
44. Kelleher, A. D., A. Carr, J. Zaunders, and D. A. Cooper. 1996. Alternations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, Ritonavir. J. Infect. Dis. 173:321-329.
45. Kishimoto, T., and T. Hirano. 1988. Molecular recognition of B-lymphocyte response. Annu. Rev. Immunol. 6:485-512.
46. Klasse, P. J. 1996. Physico-chemical analyses of the humoral immune response to HIV-1: quantification of antibodies, their binding to viral antigens and neutralization of viral infectivity, p. IV:22-52. In B. Korber, C. Brander, B. Walker, R. Koup, J. Moore, B. Haynes, and G. Myers (ed.), HIV molecular immunology database 1996. vol. 2. Los Alamos National Laboratory, Theoretical Biology and Biophysics, Los Alamos, N.Mex. http//hiv-web.lanl.gov/immuno/articles/klasse.html.
47. Klasse, P. J., and J. P. Moore. 1996. Quantitative model of antibody-mediated and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1. J. Virol. 70:3668-3677.
48. Klasse, P. J., and Q. J. Sattentau. 1996. Altered CD4 interactions of HIV type-1 LAI variants selected for the capacity to induce membrane fusion in the presence of a monoclonal antibody to domain 2 of CD4. AIDS Res: Hum. Retroviruses 12:1015-1021.
49. Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, Y. Wu, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune response with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650-4655.
50. Lange, J., D. Paul, and F. de Wolf. 1987. Viral gene expression, antibody production and immune complex formation in HIV infection. AIDS 1:15-21.
51. Lanzavecchia, A. 1985. Antigen-specific interaction between T and B cells. Nature 314:537-539.
52. Lanzavecchia, A. 1987. Antigen uptake and accumulation in antigen-specific B cells. Curr. Prog. Immunol. 99:39-51.
53. Lanzavecchia, A., and S. Bove. 1985. Specific B lymphocytes efficiently pick up, process and present antigen to T cells. Behring Institute Mitt. 77:82-87.
54. Lanzavecchia, A., E. Roosnek, T. Gregory, P. Berman, and S. Abrignani. 1988. T cells can present antigens such as HIV gp120 targeted to their own surface molecules. Nature 334:530-532.
55. Leonard, C. K., M. W. Spellman, L. Riddle, R. J. Harris, J. N. Thomas, and T. J. Gregory. 1990. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 265:10373-10382.
56. Martin-Rico, P., C. Pedersen, P. Skinhoj, C. Nielsen, and B. O. Lindhart. 1995. Rapid development of AIDS in an HIV-1 antibody-negative homosexual man. AIDS 9:95-96.
57. Mascola, J. R., S. W. Snyder, O. S. Weislow, S. M. Belay, R. B. Belshe, D. H. Schwartz, M. L. Clements, R. Dolin, B. S. Graham, G. J. Gorse, M. C. Keefer, M. J. McElrath, M. C. Walker, K. F. Wagner, J. G. McNeil, F. E. McCutchan, D. S. Burke, and the National Institute of Allergy Infectious Diseases AIDS Vaccine Evaluation Group. 1996. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J. Infect. Dis. 173:340-348.
58. Matzinger, P. 1994. Memories are made of this? Nature 369:605-606.
59. McDougal, J. S., M. S. Kennedy, S. L. Orloff, J. K. A. Nicholson, and T. J. Spira. 1996. Mechanisms of human immunodeficiency virus type 1 (HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibody. J. Virol. 70:5236-5245.
60. McKeating, J. A., A. McKnight, and J. P. Moore. 1991. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effect on infectivity and neutralization. J. Virol. 65:852-860.
61. Mizuma, H., S. Litwin, and S. Zolla-Pazner. 1988. B-cell activation in HIV-1 infection: relationship of spontaneous immunoglobulin secretion to various immunological parameters. Clin. Exp. Immunol. 71:410-416.
62. Monteflori, D. C., G. Pantaleo, L. M. Fink, J. T. Zhou, M. Bilska, G. D. Miralles, and A. S. Fauci. 1996. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J. Infect. Dis. 173:60-67.
63. Montefiori, D. C., J. Zhou, B. Barnes, D. Lake, E. M. Hersh, Y. Masuho, and L. B. Lefkowitz, Jr. 1991. Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus. Virology 182:635-643.
64. Moore, J. P., Y. Cao, D. D. Ho, and R. A. Koup. 1994. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J. Virol. 68:5142-5155.
65. Moore, J. P., Y. Cao, J. Leu, L. Qin, B. Korber, and D. D. Ho. 1996. Inter-and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J. Virol. 70:427-444.
66. Moore, J. P., Y. Cao, L. Qing, Q. J. Sattentau, J. Pyati, R. Koduri, J. Robinson, C. F. Barbas III, D. R. Burton, and D. D. Ho. 1995. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120 and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69:101-109.
67. Moore, J. P., and D. D. Ho. 1995. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. AIDS 9(Suppl. A): S117-S136.
68. Moore, J. P., and J. Sodroski. 1996. Antibody cross-competition analysis of the human immunodeficiency virus type 1 exterior envelope glycoprotein. J. Virol. 70:1863-1872.
69. Morrow, J., M. Wharton, R. Stricker, and J. Levy. 1986. Circulating immune complexes in patients with AIDS contain the AIDS-associated retrovirus. Clin. Immunol. Immunopathol. 40:515-524.
70. mac challenge following short-term infection with a Nef-deficient attenuated virus. Virology 219:195-205.
71. Oka, S., S. Ida, T. Shioda, Y. Takebe, N. Kobayashi, Y. Shibuya, K. Ohyama, K. Momota, S. Kimura, and K. Shimada. 1994. Genetic analysis of HIV-1 during rapid progression to AIDS in an apparently healthy man. AIDS Res. Hum. Retroviruses 10:271-277.
72. Pahwa, S., R. Pahwa, R. A. Good, R. C. Gallo, and C. Saxinger. 1986. Stimulatory and inhibitory influences of human immunodeficiency virus on normal B lymphocytes. Proc. Natl. Acad. Sci. USA 83:9124-9128.
73. Pantaleo, G., C. Graziosi, J. F. Demarest, L. Butini, M. Montroni, C. H. Fox, J. M. Orenstein, D. P. Kotler, and A. S. Fauci. 1993. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of infection. Nature 362:355-358.
74. Perelson, A. S., A. U. Neumann, M. Markowitz, J. M. Leonard, and D. D. Ho. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life span, and viral generation time. Science 271:1582-1586.
75. Porcelli, S., C. T. Morita, and M. B. Brenner. 1992. CD1b restricts the response of human CD4-CD8-T lymphocytes to a microbial antigen. Nature 360:593-597.
76. Robey, W. G., B. Safai, S. Oroszlan, L. O. Arthur, M. A. Gonda, R. C. Gallo, and P. J. Fischinger. 1985. Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients. Science 228: 593-595.
77. Sallusto, F., and A. Lanzaveccia. 1995. Dendritic cells use macropinocytosis and the mannose receptor to concentrate antigen in the MHC class II compartment. Downregulation by cytokines and bacterial products. J. Exp. Med. 182:389-400.
78. Sattentau, Q. J., and R. A. Weiss. 1988. The CD4 antigen: physiological ligand and HIV receptor. Cell 52:631-632.
79. Schmidt, G., K. Amiraian, H. Frey, J. Wethers, R. W. Stevens, and D. S. Berns. 1989. Monitoring human immunodeficiency virus type 1-infected patients by ratio of antibodies to gp41 and p24. J. Clin. Microbiol. 27:843-848.
80. Schwartz, D. H., L. M. Cosentino, A. Shirai, J. Conover, S. Daniel, and D. M. Klinman. 1994. Lack of correlation between the number of circulating B cells and the concentration of serum antibodies reactive with the HIV-1 envelope glycoprotein. J. Acquired Immune Defic. Syndr. 7:447-453.
81. Sheppard, H. W., M. S. Ascher, B. McRae, R. E. Anderson, W. Lang, and J.-P. Allain. 1991. The initial response to HIV and immune system activation determine the outcome of HIV disease. J. Acquired Immune Defic. Syndr. 4:704-712.
82. Shirai, A., M. Cosentino, S. F. Leitman-Klinman, and D. M. Klinman. 1992. Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation. J. Clin. Invest. 89:561-566.
83. Sieling, P. A., D. Chatterjee, S. A. Porcelli, T. I. Prigozy, R. J. Mazzaccaro, T. Soriano, B. R. Bloom, M. B. Brenner, M. Kronenberg, P. J. Brennan, and R. L. Modlin. 1995. CD1-restricted T cell recognition of microbial lipoglycan antigens. Science 269:227-230.
84. Siliciano, R. F. 1993. CD4-positive T cell responses to HIV-1 infection. Methods Immunol. 14:221-238.
85. Slifka, M. F., M. Matloubian, and R. Ahmed. 1995. Bone marrow is a major site of long-term antibody production after acute viral infection. J. Virol. 69:1895-1902.
86. Soriano, V., F. Dronda, A. Gonzalez-Lopez, F. Chaves, R. Bravo, M. Gutierrez, A. Heredia, and I. K. Hewlett. 1994. HIV-1 causing AIDS and death in a seronegative individual. Vox Sang. 67:410-411.
87. Strathdee, S. A., J. W. Frank, J. McLaughlin, M. Leblanc, C. Major, M. V. O'Shaughnessy, and S. E. Read. 1995. Quantitative measures of human immunodeficiency virus-specific antibodies predict progression to AIDS. J. Infect. Dis. 172:1375-1379.
88. Szomolanyi-Tsuda, E., and R. M. Welsh. 1996. T-cell-independent antibody-mediated clearance of polyoma virus in T cell-deficient mice. J. Exp. Med. 183:403-411.
89. Teeuwsen, V. J. P., J. M. A. Lange, R. Keet, J. K. M. E. Schattenkerk, C. Debouck, R. van der Bakker, J. Goudsmit, and A. D. M. E. Osterhaus. 1991. Low numbers of functionally active B lymphocytes in the peripheral blood of HIV-1 seropositive individuals with low p24-specific serum antibody titers. AIDS 5:971-979.
90. Trauger, R. J., F. Ferre, A. E. Daigle, F. C. Jensen, R. B. Moss, S. H. Mueller, S. P. Richieri, H. B. Slade, and D. J. Carlo. 1994. Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells. J. Infect. Dis. 169:1256-1264.
91. Tremblay, M., and M. A. Wainberg. 1990. Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera. J. Infect. Dis. 162:735-737.
92. Tsang, M. L., L. A. Evans, P. McQueen, L. Hurren, C. Byrne, R. Penny, B. Tindall, and D. A. Cooper. 1994. Neutralizing antibodies against sequential autologous human immunodeficiency virus type 1 isolates after seroconversion. J. Infect. Dis. 170:1141-1147.
93. Vallejo, A., R. Bravo, A. Heredia, V. Soriano, P. Dronda, and I. K. Hewlett. 1995. Sequence analysis of the V1/V2 and V3 domains in an HIV-seronegative AIDS patient. AIDS Res. Hum. Retroviruses 11:1539-1541.
94. Veenstra, J., I. G. Williams, R. Colebunders, L. Dorrel, S. E. Tchamouroff, G. Paton, J. M. A. Lange, I. V. D. Weller, J. Goeman, S. Uthayakumar, I. R. Gow, J. N. Weber, and R. A. Coutinho. 1996. Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons. J. Infect. Dis. 174:862-866.
95. Vogel, T., R. Kurth, and S. Norley. 1994. The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic pcptides. J. Immunol. 153:1895-1904.
96. von Gegerfelt, A., J. Albert, L. Morfeldt-Maanson, K. Broliden, and E. M. Fenyö. 1991. Isolate-specific neutralizing antibodies in patients with progressive HIV-1 related disease. Virology 185:162-168.
97. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Boenhoeffer, M. A. Nowak, B. H. Hahn, M. S. Saag, and G. M. Shaw. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122.
98. Wen, L., S. J. Roberts, J. L. Viney, F. S. Wong, C. Mallick, R. C. Findly, Q. Peng, J. E. Craft, M. J. Owen, and A. C. Hayday. 1994. Immunoglobulin synthesis and generalized autoimmunity in mice congenially deficient in alpha beta (+) T cells. Nature 369:654-658.
99. Wendler, I., U. Bienzle, and G. Hunsmann. 1987. Neutralizing antibodies and the course of HIV disease. AIDS Res. Hum. Retroviruses 3:157-163.
100. Zwart, G., L. van der Hoek, M. Valk, M. T. E. Cornelissen, E. Baan, J. Dekker, M. Koot, C. L. Kuiken, and J. Goudsmit. 1994. Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconvertors with rapid versus slow disease progression. Virology 201:285-293.